Agency’s Oncology Business Unit Receives Praise From Prominent Industry Publication


Berkeley Heights, NJ, December 19, 2016 – Today, The Access Group, a leading health care communications network, announces the recognition of its Oncology Business Unit as one of the “Most Innovative Divisions” in 2016 by the biotechnology and pharmaceutical industry magazine PM360.


“The number of promising candidates for cancer therapy is at a staggering all-time high,” said Jeffrey Gruenglas, Executive Vice President. “The Oncology Business Unit was launched out of the need to help navigate the evolving oncology landscape. With the rush of new technology and science has come new terrain and questions for the Food and Drug Administration, policy makers, managed care organizations, providers, and patients. This recognition from PM360 acknowledges the early success of a necessary and important focus of business.”


Navigating the Evolving Oncology Landscape

The Oncology Business Unit was created in February 2016. A dedicated team of oncology industry experts from backgrounds in policy, research, and cancer institutions collaborated on the identification of key trends within the expanding marketplace. “The Access Group is committed to the success of the Oncology Business Unit and our clients navigating the evolving health care landscape,” said Eric Bishea, CEO. “This commitment means continual elevation of its value with investment in key resources such as talent and strategic partnerships.”


The Oncology Business Unit applies proprietary models and tools to convert large amounts of practice and adoption pattern data into actionable insights. By partnering with Government Policy Systems, another division of The Access Group, the Oncology Business Unit uncovered implications for formulary coverage and access to care for oncology treatment manufacturers.


Charting a Course for the Biopharmaceutical Industry
With this new information and research, the Oncology Business Unit is primed to share its findings with the industry. On an ongoing basis, the team authors original publications about their insights and applies them to recommendations and guidance for manufacturers. Alternate payment models, patient financial toxicity and burden, oncology pathways, and access-centered journey simulations for any given tumor type are just a few areas manufacturers can better navigate as a result of the insights provided by the Oncology Business Unit.


Now, less than a year since its debut, the Oncology Business Unit has expanded its oncology partnerships and engagements nearly 10-fold, as measured by the number of tumor types, indications, product launches, and treatment modalities.


“Beyond research and development, the rate of oncology commercialization for underserved and challenging cancers is growing exponentially, soon to break the $100 billion ceiling,” said Gruenglas. “The Oncology Business Unit has yielded insights and strategies that are being implemented to facilitate and expedite access to care for a current range of solid tumors. We look forward to developing future applications across other oncology therapy platforms.”



About The Access Group

The Access Group is a leading independent strategic health care communications network, composed of 5 distinct entities: Bioeclipse, Catalyst, FronTier Managed Markets, MedAccess, and Promidian. Also included are 4 specialized service groups: S3 — Strategic Selling Solutions; Government Policy Systems; the Oncology Business Unit; and StrataMed. The company employs more than 130 health care marketing specialists, consultants, and senior leaders with experience in management consulting, brand promotion, marketing communications, managed markets, medical education, and training.


The Access Group is headquartered in Berkeley Heights, New Jersey, with offices in New York City, Chicago, Boston, San Diego, Los Angeles, and San Francisco. To learn more about The Access Group, please visit or contact Eric Bishea, CEO, at 908-508-6700.



Media Contact: Kristen Supchak,